The global tennis elbow treatment market is anticipated to witness considerable growth over the forecast period. Rising prevalence of elbow tendons swelling coupled with increasing incidences of pain in elbow joints are the major factors driving the global market. The repetitive motion of the elbow and arms is the main reason for tennis elbow (lateral epicondylitis). Increasing cases of lateral epicondylitis in plumbers, carpenters, swimmers, basketball players, and tennis players are also expected to propel the growth of the global lateral epicondylitis (tennis elbow) treatment market. This condition typically arises due to the extension of wrist against the resistance or improper equipment use by athletes. It has been observed that people above the age of 60 are more afflicted with tennis elbow. Therefore, the rapidly growing geriatric population base worldwide and increasing incidences of arm fractures due to accidents are expected to further fuel the market over the forecast period. However, sluggish commercialization of new effective therapies is expected to pose a hurdle for the growth of this market over the coming few years.
The overall lateral epicondylitis treatment market is classified on the basis of treatment methods into surgical therapies and non-surgical therapies. The non-surgical treatment held the largest market share as of 2014 owing to the efficiency of the treatment without operating the body. The non-surgical treatment includes extracorporeal shock wave therapy, braces, medications, and physical therapies. Various anti-inflammatory drugs (NSAIDS) such as ibuprofen, aspirin, and cortisone are administered to control pain in tennis elbow. Physical therapies such as muscle stimulation and ice massage are performed to improve healing. Moreover, straps or braces reduce the stress on elbow tendons and muscles. Extracorporeal shock wave therapy is used for promoting the natural healing process in the body. In the surgical treatment segment, arthroscopic surgery and open surgery are performed. The open surgery is expected to witness lucrative growth owing to outpatient surgeries and a high success rate of approximately 90-95% and shorter post-surgery hospital stay. Various drugs used for treatment of lateral epicondylitis include topical nitrates, botulinum toxin, and hyaluronate.
Geographically, the entire lateral epicondylitis treatment market is segmented into North America, Asia Pacific, Europe, Latin America, and MEA. As of 2014, North America held the largest market share followed by Europe. An increasing number of sports events & competitions in the U.S. coupled with increasing patient awareness levels are the vital factors for the growth of the tennis elbow treatment market in this region. Latin America and Asia regions are anticipated to grow at the highest CAGR due to the increasing incidences of sports injuries in these regions.
The global tennis elbow treatment market is consolidated in nature. Various companies are striving to gain market share by adopting competitive strategies such as joint ventures and research partnerships. Some key players operating in the market include Teikoku Pharma, Inc., Kasiak Research Pvt. Ltd., Moecular Phramacology Limited, Chugai Pharmaceutical Co., Ltd., and Seikagaku Corporation.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.